For investors

Meneldor offers investors the opportunity to co-invest in carefully selected biopharma companies grounded in strong science, robust intellectual property and clear clinical relevance. We focus on opportunities where scientific excellence and disciplined execution create the foundation for long-term value creation.

Our investment process is built on rigorous scientific and financial due diligence, continuous portfolio oversight and active engagement with management teams. We assess not only the quality of the science, but also unmet medical need, regulatory pathway, capital efficiency, risk management and exit potential.

Meneldor operates through a distinctive Dutch cooperative structure with an evergreen model. Co-investors participate directly in selected SPVs, allowing flexibility, transparency and alignment. This structure enables investors to choose participation per opportunity, while benefiting from collective negotiation power, professional syndicate management and tailored agreements.

Governance and compliance are central to our approach. We maintain a strong governance culture with clear reporting lines, structured decision-making processes and transparent communication. Our model is designed to protect investor interests, ensure regulatory compliance and foster responsible long-term stewardship in complex and highly regulated biopharma environments.

Through disciplined selection, structured governance and long-term alignment, Meneldor provides access to high-quality innovation while maintaining professional oversight and investor protection at every stage of the investment lifecycle.